About Alpha-1-acid glycoprotein 1
Alpha-1-acid glycoprotein 1 (ORM1) is a protein
from Homo sapiens identified by UniProt accession
P02763, 201 residues long.
MolForge cross-references it against 0 known binders and
468 disease associations.
Target properties
| Protein name | Alpha-1-acid glycoprotein 1 |
|---|
| UniProt accession | P02763 |
|---|
| Gene | ORM1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 201 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (468)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.38
- coagulation factor measurement · score 0.36
- testosterone measurement · score 0.34
- serum alanine aminotransferase measurement · score 0.33
- thrombin generation potential measurement · score 0.27
- tumor necrosis factor receptor 1 measurement · score 0.26
- aspartate aminotransferase measurement · score 0.24
- esophageal cancer · score 0.12
- hepatocellular carcinoma · score 0.11
- Congestive heart failure · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P02763-F1 | alphafold | PREDICTED | 89.47 | — |
Amino-acid sequence (201 residues)
MALSWVLTVL SLLPLLEAQI PLCANLVPVP ITNATLDRIT GKWFYIASAF RNEEYNKSVQ EIQATFFYFT PNKTEDTIFL REYQTRQDQC IYNTTYLNVQ RENGTISRYV GGQEHFAHLL ILRDTKTYML AFDVNDEKNW GLSVYADKPE TTKEQLGEFY EALDCLRIPK SDVVYTDWKK DKCEPLEKQH EKERKQEEGE S
Explore Alpha-1-acid glycoprotein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets